NeuExcell Therapeutics Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 11

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $14.5M

  • Investors
  • 10

NeuExcell Therapeutics General Information

Description

Developer of a gene therapy designed to treat neurodegenerative diseases and neural injuries. The company's brain repair technology utilizes in vivo astrocyte-to-neuron conversion by introducing neural transcription factors through adeno-associated virus-based gene therapy, enabling clinicians to restore damaged tissue.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 401 North Broad Street
  • Suite M125
  • Philadelphia, PA 19108
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Vertical(s)
Corporate Office
  • 401 North Broad Street
  • Suite M125
  • Philadelphia, PA 19108
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

NeuExcell Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series A) 04-May-2023 $14.5M Completed Clinical Trials - Phase 1
4. Later Stage VC Cancelled Pre-Clinical Trials
3. Later Stage VC 18-Aug-2021 Completed Pre-Clinical Trials
2. Seed Round 31-Jul-2020 $6.5M $7.35M Completed Pre-Clinical Trials
1. Angel (individual) 23-May-2016 $850K $850K Completed Startup
To view NeuExcell Therapeutics’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

NeuExcell Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a gene therapy designed to treat neurodegenerative diseases and neural injuries. The company's brain repair
Drug Discovery
Philadelphia, PA
11 As of 2025

Dallas, TX
 

Cambridge, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

NeuExcell Therapeutics Competitors (3)

One of NeuExcell Therapeutics’s 3 competitors is Taysha Gene Therapies, a Formerly VC-backed company based in Dallas, TX.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Taysha Gene Therapies Formerly VC-backed Dallas, TX
Mogrify Venture Capital-Backed Cambridge, United Kingdom
Tenaya Therapeutics Formerly VC-backed South San Francisco, CA
You’re viewing 3 of 3 competitors. Get the full list »

NeuExcell Therapeutics Patents

NeuExcell Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026114267-A1 Compositions and methods for treating alzheimer's disease in primates Pending 29-Nov-2024
AU-2024391760-A1 Compositions and methods for treating stroke in primates Pending 29-Nov-2023
EP-4816387-A1 Compositions and methods for treating stroke in primates Pending 29-Nov-2023
WO-2025113676-A1 Compositions and methods for treating stroke in primates Inactive 29-Nov-2023
AU-2024386366-A1 Gene therapy compositions and methods for treating glioma Pending 23-Nov-2023 C12N15/86
To view NeuExcell Therapeutics’s complete patent history, request access »

NeuExcell Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

NeuExcell Therapeutics Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
Fujian Haixi Pharma Corporation Minority
Guangzhou Jinkong Fund Asset Manager Minority
Jiangxi Jilinxinsheng Enterprise Management Corporation Minority
Suzhou Guofa Venture Capital Venture Capital Minority
Triwise Capital Venture Capital Minority
You’re viewing 5 of 10 investors. Get the full list »

NeuExcell Therapeutics FAQs

  • When was NeuExcell Therapeutics founded?

    NeuExcell Therapeutics was founded in 2016.

  • Where is NeuExcell Therapeutics headquartered?

    NeuExcell Therapeutics is headquartered in Philadelphia, PA.

  • What is the size of NeuExcell Therapeutics?

    NeuExcell Therapeutics has 11 total employees.

  • What industry is NeuExcell Therapeutics in?

    NeuExcell Therapeutics’s primary industry is Drug Discovery.

  • Is NeuExcell Therapeutics a private or public company?

    NeuExcell Therapeutics is a Private company.

  • What is NeuExcell Therapeutics’s current revenue?

    The current revenue for NeuExcell Therapeutics is .

  • How much funding has NeuExcell Therapeutics raised over time?

    NeuExcell Therapeutics has raised $34.8M.

  • Who are NeuExcell Therapeutics’s investors?

    Fujian Haixi Pharma, Guangzhou Jinkong Fund, Jiangxi Jilinxinsheng Enterprise Management, Suzhou Guofa Venture Capital, and Triwise Capital are 5 of 10 investors who have invested in NeuExcell Therapeutics.

  • Who are NeuExcell Therapeutics’s competitors?

    Taysha Gene Therapies, Mogrify, and Tenaya Therapeutics are competitors of NeuExcell Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process